CORONA Remedies Ltd.

•

coronaremedies.comBSE: 544644NSE: CORONA

Market Cap₹ 13,677 Cr.

Current Price

High / Low₹ 2,270 / 1,337

Stock P/E68.7

Book Value₹ 132

Price to Book12.74

Dividend Yield0.45 %

ROCE31.7 %

ROE27.4 %

Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company has a healthy return on capital (ROCE) of 30.1%
Company has a good return on equity (ROE) track record: 3 Years ROE 25.1%
Latest quarter profit grew 30.1% YoY, showing strong momentum
Operating margins have improved to 21.3% from 15.0%
Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.36x)
Company has been maintaining a healthy dividend payout of 33.0%

CONS

Total debt has risen sharply - up 127.8% year on year
Stock is trading at 12.7x its book value
Expensive relative to growth - PEG of 2.3
Rich enterprise valuation - EV/EBITDA of 31.6x

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY MICROCAP250 NIFTY TOTAL MKT

S.No.	Name
1.	SUNPHARMA	1842.00	36.54	441957.50	0.87	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9326.00	84.64	247576.00	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4975.00	86.76	189233.01	0.76	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1119.50	24.74	111670.55	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1365.00	32.72	110272.68	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1970.35	97.37	106460.42	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	DRREDDY	1161.00	30.07	96906.38	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
8.	AUROPHARMA	1675.45	25.97	96401.69	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
9.	LUPIN	2096.00	17.34	95842.92	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
10.	MANKIND	2277.00	46.04	94050.37	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2416.90	37.94	68210.88	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	CORONA	2236.30	68.72	13677.23	0.45	601.10	1201.08	4224.30	1118.99	31.74	22.05

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	314	298	294	347	361	342	353	422
	247	228	239	288	283	259	291	345
Operating Profit	67	69	54	59	78	83	62	77
OPM %	21.29%	23.32%	18.46%	16.99%	21.73%	24.29%	17.56%	18.28%
	2	1	1	2	2	-17	4	3
Interest	3	2	2	2	2	2	1	3
Depreciation	9	10	10	9	9	9	10	13
Profit before Tax	57	58	43	61	70	55	54	80
Tax %	25.07%	22.94%	27.79%	23.88%	25.08%	25.26%	17.28%	25.20%
Net Profit	0	0	0	46	52	41	45	60
	7.03	7.35	5.16	7.55	8.55	6.75	7.41	9.83

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	884	1,014	1,196	1,403	1,479
	756	860	956	1,110	1,178
Operating Profit	128	155	240	293	301
OPM %	14.48%	15.25%	20.06%	20.91%	20.34%
	7	6	6	-8	-7
Interest	4	14	11	7	8
Depreciation	20	28	37	38	42
Profit before Tax	111	118	199	240	260
Tax %	23.41%	23.61%	24.73%	23.00%	23.52%
Net Profit	85	91	149	185	199
EPS	14.57	14.80	24.43	30.27	—
Dividend Payout %	19.95%	25.00%	29.92%	33.04%	—

COMPOUNDED SALES GROWTH

10 Years:: —
5 Years:: —
3 Years:: 17%

COMPOUNDED PROFIT GROWTH

10 Years:: —
5 Years:: —
3 Years:: 30%

STOCK PRICE CAGR

10 Years:: —
5 Years:: —
3 Years:: —
1 Year:: —

RETURN ON EQUITY

10 Years:: —
5 Years:: —
3 Years:: 25%
Last Year:: 27%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	61	61	61	61
	347	419	545	686
	27	121	48	146
Trade Payables	94	114	144	147
	133	160	220	259
Total Liabilities	663	875	1,017	1,298
	185	384	370	554
Capital Work in Progress	65	121	186	143
	31	26	26	26
	105	98	129	125
	0	100	118	146
Cash & Bank	77	70	69	44
	200	77	119	260
Total Assets	663	875	1,017	1,298

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	129	157	190	229
Cash from Investing	-50	-267	-84	-256
Cash from Financing	-45	99	-107	25
	8	-11	0	-1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Dec 2025	Mar 2026	Jun 2026
	69.00	69.00	69.00
	1.84	2.25	3.63
	6.77	7.02	12.90
Government	0.00	0.00	0.00
	22.40	21.74	14.48

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-09

Spurt in Volume

2026-09-09 - Significant increase in volume has been observed in CORONA Remedies Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. CORONA Remedies Limited has submitted their response.

2026-09-09

Spurt in Volume

2026-09-09 - Significant increase in volume has been observed in CORONA Remedies Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

2026-08-20

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-20 - CORONA Remedies Limited has informed the Exchange about Schedule of meet

2026-08-10

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-10 - CORONA Remedies Limited has informed the Exchange about Transcript

2026-08-10

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-10 - CORONA Remedies Limited has informed the Exchange about Schedule of meet

2026-08-07

Updates

2026-08-07 - CORONA Remedies Limited has informed the Exchange regarding 'Machine Readable Financial results for Q1 2026-27'.

2026-08-03

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-03 - CORONA Remedies Limited has informed the Exchange about Link of Recording

2026-08-01

Copy of Newspaper Publication

2026-08-01 - CORONA Remedies Limited has informed the Exchange about Copy of Newspaper Publication

2026-07-31

Investor Presentation

2026-07-31 - CORONA Remedies Limited has informed the Exchange about Investor Presentation

News

Recent coverage and analyst commentary for CORONA

Loading news…

🤖

AI Stock Analyst

CORONA Remedies Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

SUNPHARMA

1842.00

36.54

441957.50

0.87

2901.23

26.53

15299.88

10.98

19.11

28.81

DIVISLAB

9326.00

84.64

247576.00

0.32

902.00

65.50

3080.00

27.80

21.51

40.75

TORNTPHARM

4975.00

86.76

189233.01

0.76

566.00

3.28

4921.00

57.32

19.27

33.81

ZYDUSLIFE

1119.50

24.74

111670.55

0.09

990.20

-34.90

8017.00

23.97

21.39

24.54

CIPLA

1365.00

32.72

110272.68

0.95

785.55

-39.18

7119.28

4.13

16.00

16.73

LAURUSLABS

1970.35

97.37

106460.42

0.10

362.07

123.94

2026.31

29.10

18.20

31.50

DRREDDY

1161.00

30.07

96906.38

0.69

435.60

-69.10

8099.80

-5.21

13.75

10.63

AUROPHARMA

1675.45

25.97

96401.69

0.24

1032.03

25.22

9150.35

17.44

12.76

20.54

LUPIN

2096.00

17.34

95842.92

0.86

1416.98

16.01

8276.89

34.28

28.86

29.59

MANKIND

2277.00

46.04

94050.37

0.04

574.09

29.12

4030.59

12.89

13.24

26.30

GLENMARK

2416.90

37.94

68210.88

0.10

482.83

927.88

4018.48

31.35

20.35

20.03

CORONA

2236.30

68.72

13677.23

0.45

601.10

1201.08

4224.30

1118.99

31.74

22.05

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

314

298

294

347

361

342

353

422

247

228

239

288

283

259

291

345

Operating Profit

OPM %

21.29%

23.32%

18.46%

16.99%

21.73%

24.29%

17.56%

18.28%

-17

Interest

Depreciation

Profit before Tax

Tax %

25.07%

22.94%

27.79%

23.88%

25.08%

25.26%

17.28%

25.20%

Net Profit

7.03

7.35

5.16

7.55

8.55

6.75

7.41

9.83

Mar 2023

Mar 2024

Mar 2025

Mar 2026

TTM

884

1,014

1,196

1,403

1,479

756

860

956

1,110

1,178

Operating Profit

128

155

240

293

301

OPM %

14.48%

15.25%

20.06%

20.91%

20.34%

-8

-7

Interest

Depreciation

Profit before Tax

111

118

199

240

260

Tax %

23.41%

23.61%

24.73%

23.00%

23.52%

Net Profit

149

185

199

EPS

14.57

14.80

24.43

30.27

—

Dividend Payout %

19.95%

25.00%

29.92%

33.04%

—

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Equity Capital

347

419

545

686

121

146

Trade Payables

114

144

147

133

160

220

259

Total Liabilities

663

875

1,017

1,298

185

384

370

554

Capital Work in Progress

121

186

143

105

129

125

100

118

146

Cash & Bank

200

119

260

Total Assets

663

875

1,017

1,298

Mar 2023

Mar 2024

Mar 2025

Mar 2026

129

157

190

229

Cash from Investing

-50

-267

-84

-256

Cash from Financing

-45

-107

-11

-1

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Dec 2025

Mar 2026

Jun 2026

69.00

1.84

2.25

3.63

6.77

7.02

12.90

Government

0.00

22.40

21.74

14.48

CORONA Remedies Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

CORONA Remedies Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI